Abstract 620P
Background
Angiogenesis is a crucial mechanism in colorectal cancer (CRC) development and progression, and anti-angiogenic drugs are a mainstay of CRC systemic treatment.
Methods
We conducted, according to Simon’s “minimax” two stage design, an open-label, single arm phase II trial to evaluate the antitumor activity of cabozantinib in pretreated metastatic CRC (mCRC) patients (pts), that progressed after at least 2 lines of prior therapy for metastatic disease. The primary endpoint was the Progression Free Survival (PFS) rate at 16 weeks; secondary endpoints include PFS, Overall Survival (OS), Response Rate (RR), Disease Control Rate, safety. Here we present the initial exploratory biomarkers analysis.
Results
From October 2019 to January 2023 a total of 33 (19 male and 14 female) pts, median age of 58 years (30-79), were treated with cabozantinib 60 mg/daily per os. A comprehensive genomic profiling by next generation sequencing (NGS) was performed with FoundationOne CDx and FoundationOne Liquid CDx (324 genes) on tumor tissue (20/33) and plasma circulating tumor DNA (ctDNA) (15/33) both in 8/33 pts. 11 out of 33 patients were free of progression at 16 weeks and were considered responders and among these the NGS analysis was available at the time of abstract submission in 10 pts. No specific genetic feature was identified in responders, only 1 patient had AXL amplification (that represents a potential target of cabozantinib). Of note MET amplification found in 2/25 pts did not correlate with response to cabozantinib. In not responding pts SMAD4 mutation as well as genetic alteration defying a “BRCAness" phenotype were most reported. RNASeq analysis is currently ongoing in 26/33 (78.8%) patient samples.
Conclusions
The ABACO study showed clinical activity of cabozantinib in a subset of refractory mCRC, to the date of the analysis no predictive markers were identified so far. Further analysis are ongoing.
Clinical trial identification
EudraCT 2019-000674-28.
Editorial acknowledgement
Legal entity responsible for the study
Department of Precision Medicine.
Funding
Ipsen partially funded.
Disclosure
F. Ciardiello: Financial Interests, Personal, Advisory Board: Roche, Merck Serono, Servier, Pierre Fabre, Pfizer; Financial Interests, Institutional, Research Grant: Merck Serono, Roche, Amgen; Financial Interests, Institutional, Local PI: Pfizer, Pierre Fabre, Servier. E. Martinelli: Financial Interests, Personal, Invited Speaker: Merck-Serono, Bayer, Merck S.p.a, ESMO; Financial Interests, Personal, Writing Engagement, Advisory board and invited speaker and travel grant: Pierre Fabre; Financial Interests, Personal, Writing Engagement, Advisory board and Invited speakers: INCYTE; Financial Interests, Personal, Writing Engagement, Advisory board and invited speaker: Servier, Roche; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Writing Engagement, Travel grant: AstraZeneca; Financial Interests, Personal, Writing Engagement, Advisory board: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10
539P - Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Presenter: Eduard Teixidor Vilà
Session: Poster session 10
540P - Impact of adjuvant radiotherapy (ART) on survival time in patients with hemangiopericytoma (HPC): A population study
Presenter: Tala Alshwayyat
Session: Poster session 10
541P - A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Presenter: Manuel Mazariegos Rubi
Session: Poster session 10
542P - Drug screening in Li-Fraumeni syndrome brain tumor models
Presenter: Anna Kolodziejczak
Session: Poster session 10
543P - Bevacizumab and hydroxyurea treatment in grade 2 and 3 meningioma: A monocentric experience
Presenter: Giulia Cerretti
Session: Poster session 10
544P - Clinical and molecular features of primary central nervous system tumor with Lynch syndrome
Presenter: Nan Liu
Session: Poster session 10
545P - Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma
Presenter: Judith Niesen
Session: Poster session 10
546P - Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Presenter: Alexandre Bertucci
Session: Poster session 10
547P - Clinicopathological and molecular study of embryonal tumours with multilayered rosettes
Presenter: Lianghong Teng
Session: Poster session 10